-
1.发明公开
公开(公告)号：EP3302484A1
公开(公告)日：2018-04-11
申请号：EP16804001.2
申请日：2016-05-24
Applicant: Merck Sharp & Dohme Corp. , MSD R&D (China) Co., Ltd.
Inventor： SHEN, Dong-Ming , DWYER, Michael, P. , SINZ, Christopher, J. , WANG, Deping , STACHEL, Shawn, J. , PAONE, Daniel, V. , FORSTER, Ashley , BERGER, Richard , SHIPE, William, D. , CHEN, Yili , QIAN, Yimin , XU, Shimin , HU, Chunmei , FU, Jianmin , GUO, Zhigang , LI, Haitang , BO, Yingjian
IPC: A61K31/519 , A61P25/28 , C07D487/04
CPC classification number: C07D487/04 , A61K31/519 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28
Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：EP3302486A1
公开(公告)日：2018-04-11
申请号：EP16804194.5
申请日：2016-05-31
Applicant: Merck Sharp & Dohme Corp. , MSD R&D (China) Co., Ltd.
Inventor： SHEN, Dong-Ming , DWYER, Michael P. , SINZ, Christopher J. , WANG, Deping , STACHEL, Shawn , PAONE, Daniel V. , FORSTER, Ashley , BERGER, Richard , CHEN, Yili , QIAN, Yimin , XU, Shimin , HU, Chunmei
IPC: A61K31/519 , A61P25/28 , C07D487/04
Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
3.发明公开
公开(公告)号：EP3087060A1
公开(公告)日：2016-11-02
申请号：EP14873215.9
申请日：2014-12-17
Applicant: Merck Sharp & Dohme Corp. , MSD R & D (China) Co. Ltd.
Inventor： SHEN, Dong-Ming , EGBERTSON, Melissa , BERGER, Richard , QIAN, XiaoXia , QIAN, Yimin , HARPER, Bart , YANG, Meng , GUO, Zack Zhi Qiang , RADA, Vanessa L. , WANG, Deping , CERNAK, Timothy A. , SINZ, Christopher J. , WANG, Ming , WILSON, Jonathan E. , XU, Shimin
IPC: C07D239/36 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , A61K31/513 , A61P25/18 , A61P25/22 , A61P25/28
CPC classification number: C07D239/36 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/04 , C07D487/04
Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
Abstract translation: 公开了式（I）的嘧啶羧酰胺化合物，其可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病，药物组合物及其用途的治疗剂。
-
公开(公告)号：EP3302486B1
公开(公告)日：2020-09-30
申请号：EP16804194.5
申请日：2016-05-31
Applicant: Merck Sharp & Dohme Corp. , MSD R&D (China) Co., Ltd.
Inventor： SHEN, Dong-Ming , DWYER, Michael P. , SINZ, Christopher J. , WANG, Deping , STACHEL, Shawn , PAONE, Daniel V. , FORSTER, Ashley , BERGER, Richard , CHEN, Yili , QIAN, Yimin , XU, Shimin , HU, Chunmei
IPC: A61K31/519 , A61P25/28 , C07D487/04
-
公开(公告)号：EP3302484B1
公开(公告)日：2020-09-16
申请号：EP16804001.2
申请日：2016-05-24
Applicant: Merck Sharp & Dohme Corp. , MSD R&D (China) Co., Ltd.
Inventor： SHEN, Dong-Ming , DWYER, Michael, P. , SINZ, Christopher, J. , WANG, Deping , STACHEL, Shawn, J. , PAONE, Daniel, V. , FORSTER, Ashley , BERGER, Richard , SHIPE, William, D. , CHEN, Yili , QIAN, Yimin , XU, Shimin , HU, Chunmei , FU, Jianmin , GUO, Zhigang , LI, Haitang , BO, Yingjian
IPC: A61K31/519 , A61P25/28 , C07D487/04
-
Patent Agency Ranking
公开(公告)号：EP3087060B1
公开(公告)日：2020-05-13
申请号：EP14873215.9
申请日：2014-12-17
Applicant: Merck Sharp & Dohme Corp. , MSD R&D (China) Co., Ltd.
Inventor： SHEN, Dong-Ming , EGBERTSON, Melissa , BERGER, Richard , QIAN, XiaoXia , QIAN, Yimin , HARPER, Bart , YANG, Meng , GUO, Zack Zhi Qiang , RADA, Vanessa L. , WANG, Deping , CERNAK, Timothy A. , SINZ, Christopher J. , WANG, Ming , WILSON, Jonathan E. , XU, Shimin
IPC: C07D239/36 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , A61K31/513 , A61P25/18 , A61P25/22 , A61P25/28
-
公开(公告)号：EP3270926A1
公开(公告)日：2018-01-24
申请号：EP16765473.0
申请日：2016-03-11
Applicant: Merck Sharp & Dohme Corp.
Inventor： SHEN, Dong-Ming , SINZ, Christopher J. , CRESPO, Alejandro , WILSON, Jonathan E. , MCCRACKEN, Troy , XU, Shimin , LI, Haitang
IPC: A61K31/513 , C07D401/04 , C07D401/14
CPC classification number: C07D403/04 , A61P25/00 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：EP3104705A1
公开(公告)日：2016-12-21
申请号：EP15748498.1
申请日：2015-02-06
Applicant: Merck Sharp & Dohme Corp.
Inventor： STACHEL, Shawn , PAONE, Daniel V. , LI, Jing , GINNETTI,Anthony , FU, Jianmin , XU, Shimin
IPC: A01N43/56
CPC classification number: C07D401/10 , A61K31/415 , A61K31/4155 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D231/12 , C07D401/04 , C07D403/04 , C07D403/10 , C07D471/04
Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Abstract translation: 本发明涉及一类新的化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于组织蛋白酶K，L，S和B的抑制剂。这些化合物可用于治疗其中指出骨吸收抑制的疾病，例如 骨质疏松症。
-
公开(公告)号：EP3313397A1
公开(公告)日：2018-05-02
申请号：EP16818503.1
申请日：2016-06-24
Applicant: Merck Sharp & Dohme Corp.
Inventor： MCGOWAN, Meredeth Ann , ZHOU, Hua , KATZ, Jason, D. , YANG, Lihu , METHOT, Joey, L. , LIPFORD, Kathryn Ann , XU, Shimin , FU, Ning , XU, Guoquan , BIAN, Deqian , FU, Jianmin , LI, Yabin , FONG, Kin Chiu
IPC: A61K31/397 , A61K31/505 , C07D473/34
CPC classification number: C07D473/30 , A61K45/06 , A61P11/00 , A61P11/06 , A61P11/08 , A61P17/06 , A61P19/02 , A61P35/00 , A61P37/00 , C07D471/04 , C07D473/34 , C07D519/00
Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
-
公开(公告)号：EP3054947A1
公开(公告)日：2016-08-17
申请号：EP14852717.9
申请日：2014-10-03
Applicant: Merck Sharp & Dohme Corp.
Inventor： STACHEL, Shawn , PAONE, Daniel V. , LI, Jing , GINNETTI, Anthony , LIM, John , FU, Jianmin , XU, Shimin
IPC: A61K31/425 , A61K31/42 , C07D277/02 , C07D263/02
CPC classification number: C07D277/30 , A61K31/415 , A61K31/427 , A61K31/44 , A61K31/4439 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D231/12 , C07D263/22 , C07D263/32 , C07D277/22 , C07D277/34 , C07D277/52 , C07D405/04 , C07D417/04 , C07D417/10 , C07D417/14 , Y02A50/423 , A61K2300/00
Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Abstract translation: 本发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于组织蛋白酶K，L，S和B的抑制剂。这些化合物可用于治疗其中指示抑制骨吸收的疾病，例如 骨质疏松症。
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.031 seconds)
